לברסט

Land: Israel

Språk: hebreiska

Källa: Ministry of Health

Aktiva substanser:

LETROZOLE 2.5 MG

Tillgänglig från:

RAFA LABORATORIES LTD

ATC-kod:

L02BG04

Läkemedelsform:

FILM COATED TABLETS

Administreringssätt:

PER OS

Tillverkad av:

SIEGFRIED GENERICS ( MALTA) LTD

Terapeutisk grupp:

LETROZOLE

Terapeutiska indikationer:

Letrozole tablets are indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whom hormone receptor status cannot be determined locally advanced or metastatic breast cancer. Letrozole is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. Extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy. Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

Tillstånd datum:

2012-04-01